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Diagnosis and treatment of coronary artery
disease in hemodialysis patients evaluated
for transplant
Jose JG De Lima1*, Luis Henrique W Gowdak1 and Flavio J de Paula2
Abstract
We present a review of current strategies for the diagnosis and treatment of coronary artery disease (CAD) in
patients with advanced chronic kidney disease who are on the waiting list for transplants, based on data from the
literature and originated from a single-center cohort of 1,250 patients with maximum follow-up of 12 years. We
discuss the best way to select patients to be tested for CAD, how to choose the more adequate screening test for
CAD and cardiovascular disease, how to select patients for invasive treatment studies and how to treat patients
with significant CAD. We also suggest new research avenues to be explored to resolve some problems in this area.
Keywords: Chronic kidney disease, Coronary artery disease, Renal transplantation, Myocardial scintigraphy, Coronary
angiography
Introduction
Compared to the general population, patients with chronic
kidney disease (CKD) are at the highest risk of developing
cardiovascular complications and dying [1]. This trend has
been observed in individuals with moderate reduction in
renal function and increases as renal insufficiency pro-
gresses [2]. The adjusted risk of cardiovascular death for
patients on dialysis is 10 to 20 times higher than that in
the general population, and 50% of such deaths are related
to coronary artery disease (CAD) [3,4]. Also, patients with
CKD have a worse prognosis once one event has occurred
[5], thus most patients with CKD are more likely to die as
a result of cardiovascular disease (CVD) than to reach the
final stages of renal failure and be started on renal replace-
ment therapy [6]. The prevalence of significant CAD
(>50% stenosis) in dialysis patients varies between 30%
and 70% and is greatly influenced by age and the presence
of diabetes as well as by the use of angiography as a diag-
nostic method [7-12]. Renal transplantation is associated
with improved survival [13], but CVD remains the most
common cause of death after transplantation [14]. To-
gether, these facts justify the routine assessment of patients
with CKD for associated CVD and CAD, including those
being considered for kidney transplantation.
The optimal way to screen for and manage CAD prior
to and following kidney transplantation is a topic of in-
tense debate in the literature. There is no firm consensus
about who should be tested, which testing modality should
be used and who should undergo intervention if CAD is
found [15-18]. In 1997, our center started a prospective,
observational study intended to determine the best clinical
and cardiovascular investigations for the detection of CAD
and the prediction of cardiovascular events in patients
evaluated for kidney transplants. The cohort now encom-
passes 1,250 patients with a median follow-up of
38 months. The present article is based on the database
and data collected during the follow-up periods, as well as
on pertinent observations reported in the literature.
Which patients should be tested for CAD?
According to the American Society of Transplantation
(AST) guidelines, the elderly, patients with diabetes and
patients with associated clinical CVD (high-risk patients)
should be tested for CAD [15]. High-risk patients are
clinically defined by clinical evidence of actual or past
vascular arterial disease, heart failure and previous stroke
or myocardial infarction. Which patients should be con-
sidered at low risk is unclear, however; that is, young
patients (< 50 years old), patients without diabetes and
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those with no clinical evidence of CVD should also be
tested, because CKD is considered an independent risk
factor for cardiovascular death. Therefore, we tested the
hypothesis that clinical stratification alone would make
detailed cardiac evaluation unnecessary in low-risk
patients [19]. We evaluated 363 consecutive candidates
for renal transplantation followed up for 51 months. We
found that only 1 of 93 low-risk patients had an adverse
event (stroke), and no coronary events were observed.
Contrary to that finding, 49 adverse events occurred in
270 high-risk patients, comprising 12 strokes, 12 sudden
deaths, 11 cases of unstable angina, 6 myocardial infarc-
tions, 4 congestive heart failures requiring hospitalization
and 4 acute peripheral vascular events resulting in inter-
vention. Of these adverse events, 29 (58%) were attribu-
ted to CAD (sudden cardiac death, myocardial infarction
and unstable angina). These results indicate that in-
depth cardiac investigation is not required in low-risk
asymptomatic patients and that clinical stratification is
an adequate tool to identify subjects at high risk for fu-
ture cardiovascular events.
What is the best screening test for CAD and
cardiovascular events in high-risk patients?
Guidelines for the detection of CAD and assessment of risk
in CKD patients are based on the results of noninvasive
testing, such as myocardial scanning (dipyridamole stress
testing single-photon emission-computed tomography
(SPECT)) and echocardiography stress testing (EST) with
dobutamine-atropine on the basis of data derived from the
nonuremic population [20]. In the majority of cases, the
accuracy of these tests in patients with CKD was evaluated
by the incidence of adverse events, with the invasive test
reserved for those patients with evidence of ischemia. On
the basis of using this approach, the sensibility and specifi-
city of SPECT have been found to be highly variable by di-
verse authors, usually lower than 80% [21-26].
It is important to point out that epidemiological stud-
ies have indicated that a useful diagnostic test for a con-
dition that is highly prevalent, such as CAD in CKD
patients, must have sensitivity and specificity of at least
80%. The negative predictive value, which incorporates
the disease prevalence in its formula, should be even
higher. Otherwise, a negative test is likely to represent a
false-negative result.
We evaluated prospectively the accuracy of these two
noninvasive tests in detecting CAD (≥70% stenosis) and
assessing cardiovascular risk using coronary angiography
as the “gold standard” in 126 high-risk patients classified
according to the AST criteria [8]. The prevalence of CAD
was 42%. The sensitivity and negative predictive values of
both noninvasive tests for the detection of CAD were
<75%, meaning that the tests failed to identify almost one-
third of patients with significant coronary stenosis. More
importantly, CAD, but not the noninvasive tests, corre-
lated with adverse events with a sensitivity of 86% and a
negative predictive value of 96%. The relative risk of ad-
verse events for patients with CAD was almost 10 times
higher, and CAD was the only variable significantly related
to adverse events in multivariate analysis. Therefore, we
concluded that the current noninvasive tests are of limited
usefulness to select high-risk patients for coronary angiog-
raphy and for risk stratification.
Are there alternatives to SPECT and EST? Exercise elec-
trocardiography may be helpful but cannot be used in
many CKD patients because of their low tolerance to exer-
cise [27]. Cardiac computed tomographic angiography has
not been evaluated extensively in this population, and car-
diac magnetic resonance imaging is no longer indicated
for patients with renal disease, owing to the risk of gado-
linium-associated systemic fibrosis [28]. In our center, the
accuracy of the coronary calcium score as a predictor of
CAD was found to be comparable to SPECT (area under
the receiver operating characteristic curve= 0.70) [29]. We
may say that there is still no totally satisfactory screening
method for CAD in this group of patients.
Should all high-risk patients undergo coronary
angiography?
Because of the suboptimal performance of current nonin-
vasive testing to detect CAD and stratify patients for car-
diovascular risk, clinicians at some centers advocate the
use of an invasive test for all high-risk patients. Certainly,
relying only on noninvasive tests would cause 20% to 30%
of high-risk patients with CAD to be undiagnosed. How-
ever, coronary angiography is expensive and not without
risks. Moreover, the majority of studies have conclusively
shown that the prevalence of CAD in the high-risk
patients evaluated by angiography is, on average, close to
50%. This means that, if we accept that approach, a signifi-
cant proportion of patients will be exposed to invasive test-
ing with no clear clinical advantage. Therefore, in our
center, we are working to find ways to identify, among
high-risk patients, those with a higher probability of occult
significant coronary stenosis and, as a consequence, more
likely to benefit from angiography.
Our hypothesis is that the levels of risk imparted by age,
presence of diabetes and diverse associated CVD are not
the same. For that reason, we sought to determine the
clinical predictors more closely related to CAD in 301
renal transplant candidates treated by hemodialysis [30].
CAD (≥70% stenosis) was found in 45% of cases, and the
clinical variables significantly associated with CAD were
diabetes, peripheral vascular disease and previous myocar-
dial infarction. More importantly, the prevalence of CAD
increased with the number of clinical predictors from 26%
(none) to 100% (all present), whereas the incidence of
events increased two-, four- and sixfold in those with
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diabetes, vasculopathy or previous myocardial infarction,
respectively (P< 0.0001). Using these clinical parameters
to select patients for invasive testing would allow the re-
duction of the prevalence of unnecessary angiography
from 55% (when all patients undergo angiography) to 26%.
However, missing the diagnosis of CAD in one-fourth of
patients is still not satisfactory. Therefore, we are now
seeking to refine this score by finding the precise influence
of each relevant factor on prognosis. The preliminary
results of this project have recently been reported [31]. In
this way, we hope to find a means by which to reduce the
number of invasive tests without compromising the ability
to correctly identify patients with significant CAD. Mean-
while, we advocate coronary angiography for symptomatic
patients, those with altered myocardial scans (either transi-
ent or fixed defects) and individuals with associated CVD,
irrespective of symptoms or the results of noninvasive test-
ing. Patients with diabetes types 1 and 2 who do not have
any of the aforementioned characteristics, and regardless
of how long they have had diabetes, do not undergo rou-
tine invasive evaluation.
Management of coronary artery disease in patients with
end-stage renal disease
Clinical management
In the current era of so-called “evidence-based medi-
cine,” the treatment of patients with CKD and concomi-
tant CAD should be based on solid data gathered from
randomized clinical trials that included a large number
of patients. Despite the indisputable fact that CAD is of
great importance as a major determinant of cardiovascu-
lar morbidity and mortality in patients with CKD, our
knowledge of how best to treat CAD in this special
group of patients is less clear by far than what we already
know regarding the management of CAD in patients
without CKD. The main reason is that patients with
CKD are consistently more often excluded from cardio-
vascular trials than patients with other comorbidities,
such as diabetes, hypertension or smoking. In a paper by
Charytan and Kuntz, who reviewed 86 cardiovascular
trials that randomized more than 400,000 patients, 80%
of the trials excluded subjects with end-stage renal dis-
ease (ESRD), whereas baseline renal function was
reported in only 7% of the trials [32].
The simple transposition of a proven therapeutic strat-
egy in reducing cardiovascular morbidity and mortality in
patients with CAD and preserving renal function in those
with CAD and CKD may not be so simple after all. Two
recent clinical trials have proven that point exactly. Since
the first publication of the Scandinavian Simvastatin Sur-
vival Study in the mid-1990s, statin therapy has become
one of the cornerstones of the management of patients
with proven CAD (and patients at high risk for CAD) and
no CKD [33]. On the other hand, in both the 4D and
AURORA studies, the use of atorvastatin or rosuvastatin,
respectively, in patients at high cardiovascular risk under-
going hemodialysis failed to decrease the composite pri-
mary end point of cardiovascular death, nonfatal
myocardial infarction or nonfatal stroke, even in those
subgroups of patients with diabetes, a history of CVD or
high levels of low-density lipoprotein (LDL) cholesterol or
high-sensitivity C-reactive protein [34,35].
We must point out, however, that in both studies less
than 40% of enrolled patients had any form of atheroscler-
otic CVD, including CAD, so those studies were not per-
formed exclusively in patients with CAD and CKD. It is
our understanding that if a patient presents with docu-
mented CAD, regardless of renal function status, statin
therapy should be initiated and maintained, targeted to a
level of LDL cholesterol below 70 mg/dl. In fact, two post
hoc studies of the 4D and AURORA data indicate that sta-
tins may reduce cardiac events in selected groups of
patients treated by dialysis [36,37]. In patients with a wide
range of renal insufficiency, not necessarily on dialysis, the
recent SHARP trial also showed a beneficial effect of sim-
vastatin plus ezetimibe on the incidence of major athero-
sclerotic events [38]. There is a clear tendency toward
recommending statin therapy according to the criteria for
the general population in patients with CKD. On the other
hand, it is still unclear if statins should also be recom-
mended for CKD patients with no risk factors for coronary
events as defined for the general population.
In light of the lack of studies specifically conducted in
patients with CKD and CAD, we recommend following
the current guidelines for the overall medical management
of patients with chronic CAD proposed by the American
Society of Cardiology and American Heart Association or
the European Society of Cardiology, which have been advo-
cated by the National Kidney Foundation Task Force on
Cardiovascular Disease since the late 1990s [39-41]. This
multifaceted approach to overall cardiovascular risk reduc-
tion includes, in addition to lifestyle modifications (diet,
physical activity and smoking cessation), statins and aspirin
for all patients. β-blockers should be used in patients with
symptomatic angina and/or after myocardial infarction as
well as in patients with CAD and left ventricular dysfunc-
tion. Angiotensin-converting enzyme (ACE) inhibitors (or
angiotensin type II receptor blockers (ARBs)) should be
used in hypertensive patients with CAD with or without
diabetes, as well as in patients with left ventricular dysfunc-
tion. Attention should be paid not only to initiating those
drugs in patients with CAD and CKD on dialysis but also
to keeping them on those drugs in cases of patients who
undergo kidney transplantation, thereby minimizing the
risk of a periprocedural cardiovascular event that could
jeopardize the overall benefit conferred by an otherwise
successful transplant. The possibility that renin-angiotensin
blockers may cause serum creatinine levels to fall more
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slowly in recipients of live donor renal transplants still
needs confirmation [42]. The dire consequences of coron-
ary events during and in the early posttransplantation
period should be always considered, however, even if some
adverse side effects are anticipated.
This cardioprotective selection of drugs is increasingly
being used in patients with CAD, however, for reasons
that are still unclear, the prescription of these cardiopro-
tective medications is less frequent among patients with
CKD compared to the general population. In a previous
study, we showed that in 119 patients with ESRD and
CAD followed in a single center, the baseline use of as-
pirin and statins, in the range of 52% and 17%, respect-
ively, was unexpectedly low [43]. In the same study, the
use of ACE inhibitors (or ARBs) in 103 patients with dia-
betes and CKD was only 34%.
Thus, regarding the medical management of patients
with CAD and stage V CKD, clinicians face two major
challenges: (1) the lack of clinical trials specifically
designed to assess the extension of the benefit of modern
medical treatment and (2) the therapeutic nihilism that
keeps physicians and healthcare providers from prescrib-
ing cardioprotective drugs with proven benefit in redu-
cing cardiovascular mortality in the overall population.
Myyocardial revascularization: percutaneous coronary
intervention or coronary artery bypass graft
The American Heart Association and American College
of Cardiology recently jointly issued a document regard-
ing criteria for the appropriateness of myocardial revas-
cularization in patients with stable angina [44]. Briefly,
myocardial revascularization procedures are indicated on
the basis of three distinct elements: clinical presentation
(that is, angina functional class), the results of noninva-
sive testing (stress-induced myocardial ischemia) and the
extension of obstructive lesions. Patients who are more
symptomatic and receiving optimal medical therapy with
high-risk results evidenced by noninvasive tests and
more extensive CAD should be referred for myocardial
revascularization procedures. Again, in light of the lack
of trials specifically designed to study patients with CAD
and CKD, we are compelled to apply the same criteria
established for patients with preserved renal function to
patients with CKD.
There are two major caveats to that approach. The first
one is that patients with ESRD are usually self-limited
regarding physical activity, which may mask exercise-
induced ischemia as a diagnostic clue to the severity of
CAD. Moreover, even when patients do present with
acute coronary syndrome, fewer with renal failure will
have chest pain compared to those with normal renal
function, making the clinical suspicion of CAD even
more challenging [45]. The second issue relates to non-
invasive testing for the diagnosis of CAD in patients with
CKD. It is well-accepted now that the overall sensitivity
and specificity for the diagnosis of CAD in patients with
CKD are lower than those found in patients with normal
renal function [46]. Therefore, clinicians may miss two
of the three important elements that could lead to a clear
indication for myocardial revascularization.
If one finally manages to overcome the previously
alluded difficulties in the decision-making process and
decides to refer a patient for a myocardial revasculariza-
tion procedure, another question immediately follows:
What kind of revascularization technique should be
used, percutaneous or surgical?
As a general rule, the results of coronary interventions
in patients with ESRD undergoing dialysis are worse than
those performed in the general patient population. In vari-
ous retrospective studies, perioperative death during cor-
onary bypass graft (CABG) surgery in patients with ESRD
undergoing dialysis varies from 5% to 20%, roughly three
to four times higher than the rate in the general patient
population. The 5-year mortality in CABG patients with
ESRD who are undergoing dialysis is about 48%, compared
with 15% in the general patient population [47].
Given the higher mortality rates in patients with CKD
who undergo CABG surgery, referring a patient for such
a risky procedure can be made only if the procedure not
only provides symptom relief but also yields a clear re-
duction in mortality compared to those patients kept on
medical treatment. In this regard, an early retrospective
investigation showed that dialysis patients who under-
went CABG surgery had a better prognosis than those
treated medically [48]. A subsequent small, prospective
study in hemodialysis patients with diabetes also showed
that coronary intervention (surgery or angioplasty) was
associated with reduced cardiac mortality and events
[49]. It should be mentioned, however, that in both stud-
ies medical therapy was suboptimal by current standards.
More recently, we looked at the impact of modern med-
ical treatment of CAD compared to myocardial revascu-
larization on the long-term occurrence of events in a
registry of 230 patients with CKD and documented sig-
nificant CAD (≥70% stenosis). In that study, 184 patients
were kept on medical treatment and 46 were referred for
myocardial revascularization, although 16 of them refused
the procedure [50]. The event-free survival rates at 12 and
48 months were 86% and 61%, respectively, for patients
kept on medical treatment alone and 97% and 79%, re-
spectively, for those who had any revascularization proced-
ure. Among those who refused the procedure, however,
the event-free survival rate at 48 months was only 26%.
We concluded that medical therapy in selected patients
promotes acceptable long-term event-free survival rates
and that failure to intervene may lead to an adverse out-
come when myocardial revascularization was clearly indi-
cated on the basis of the current guidelines.
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In another study, Herzog and colleagues collected
data from the US Renal Data System to compare the
long-term survival of 15,784 dialysis patients after per-
cutaneous angioplasty, coronary stenting or CABG sur-
gery [51]. The 2-year all-cause survival rate was
56.4 ± 1.4% (CABG surgery), 48.2 ± 1.5% (angioplasty)
and 48.4 ± 2.0% (coronary stenting). There was a statis-
tically significant difference between the groups that
indicated superior results of surgery over the other
types of treatment.
Current data support previous observations regarding
the overall superior benefit of CABG surgery over percu-
taneous coronary intervention (PCI) with drug-eluting
stents (DESs) in patients with CKD on hemodialysis. In a
small, nonrandomized study, Sunagawa et al. compared
the event-free survival rates in patients with CKD on
hemodialysis who underwent either CABG surgery
(n= 29) or PCI (n= 75) [52]. They were able to show that
at 2-year follow-up, the cardiac death rate was 0% for
the patients who had CABG procedures and 16% for
PCI-treated patients. During the later follow-up period,
there were six deaths in the CABG group and twenty-
seven (including six sudden deaths) in the PCI group.
These authors concluded that the use of DESs in this pa-
tient population carries a higher risk for sudden death
which might be due to stent thrombosis.
As we have discussed, the currently available data gath-
ered is based on either (1) registries of patients with
CKD and significant CAD that look retrospectively at
outcomes according to different therapeutic strategies or
(2) post hoc analysis of subgroups of patients with CKD
prospectively enrolled in cardiovascular trials. What we
are in great need of is a randomized clinical trial that
enrolls only patients with CKD and significant CAD in
whom both strategies (medical and invasive treatments)
are equally justifiable based on current guidelines. Such a
study has been proposed [53] and would provide the best
evidence for choosing the right therapeutic strategy for
treating CAD in this high-risk group of patients.
Conclusion
CAD is a common and important complication in
patients with advanced CKD. Because patients with CKD
are frequently excluded from cardiovascular trials, no
clear strategies have been developed specifically for the
detection and treatment of CAD in these patients. That
is one of the reasons for the erratic and disappointing
results reported in the diagnosis and treatment of CAD
in this population. Clinicians are in great need of rando-
mized clinical trials that enroll solely patients with CKD
in whom diagnostic and treatment strategies are tested
based on current guidelines. Such studies would provide
the best evidence for choosing the right strategy to
screen and treat CAD in this high-risk group of patients.
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